RWA Wealth Partners LLC Purchases 2,461 Shares of Cencora, Inc. $COR

RWA Wealth Partners LLC raised its position in Cencora, Inc. (NYSE:COR) by 7.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,625 shares of the company’s stock after purchasing an additional 2,461 shares during the quarter. RWA Wealth Partners LLC’s holdings in Cencora were worth $11,759,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Vermillion & White Wealth Management Group LLC boosted its holdings in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the period. Cloud Capital Management LLC purchased a new stake in Cencora in the 3rd quarter valued at about $31,000. Westside Investment Management Inc. grew its stake in Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares in the last quarter. Copia Wealth Management grew its stake in Cencora by 505.0% in the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after purchasing an additional 101 shares in the last quarter. Finally, Caldwell Trust Co bought a new stake in Cencora during the 2nd quarter valued at $46,000. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Wells Fargo & Company boosted their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Barclays increased their price target on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Finally, Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $364.80 on Wednesday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The business has a fifty day moving average of $350.19 and a 200 day moving average of $332.57. The firm has a market capitalization of $70.96 billion, a price-to-earnings ratio of 43.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.68. Cencora, Inc. has a 1 year low of $244.97 and a 1 year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the prior year, the company earned $3.73 earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.